
Pemigatinib demonstrates significant efficacy in the treatment of cholangiocarcinoma, so its price has attracted considerable attention from patients. However, due to differences in manufacturers and distribution channels of pemigatinib, there are variations in the prices of different versions of the drug. When using pemigatinib for cholangiocarcinoma treatment, patients should consult doctors in detail to ensure accurate and safe medication use.
What is the Price of Imported Authentic Pemigatinib?
What are the Price Differences Between Different Versions of Pemigatinib?
The Lucius (Laos) version of pemigatinib has a specification of 4.5mg * 14 tablets, with a price of $900 per box.
The Boke Long Pharmaceutical (Paraguay) version of pemigatinib has a specification of 4.5mg * 21 capsules, priced at $2,850 per box.
The Hong Kong (China) version of Pemazyre (pemigatinib) has a specification of 13.5mg * 14 tablets, costing $69,600.
The above prices are for reference only. The actual price may change due to market fluctuations and policy impacts. Up to now, pemigatinib has not been included in medical insurance in China, so it cannot be reimbursed through medical insurance. For most patients, the price remains a major "worry" during treatment.
How to Administer Pemigatinib and What Adverse Reactions Does It Have?
Although pemigatinib shows remarkable clinical efficacy in treating cholangiocarcinoma patients, there are still many questions among patients regarding its administration and adverse reactions. The following sections will detail the dosage and administration of pemigatinib as well as its adverse reactions to help patients better understand and use this drug.
What is the Dosage and Administration of Pemigatinib?
The recommended dose is 13.5mg taken orally once daily for 14 consecutive days, followed by 7 days of rest within a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity occurs.
Swallow the tablets whole; do not crush or split them. They can be taken with or without food.
What Adverse Reactions May Occur During Pemigatinib Administration?
Diarrhea, nausea, taste changes
Vomiting, loss of appetite, weight loss
Constipation, stomach pain, mouth sores
Dry mouth and/or dry skin; decreased urine output; or rapid heartbeat
Onychia (nail inflammation), alopecia (hair loss), headache
Fatigue, joint pain, painful urination, swelling and pain in limbs or joints
Blurred vision, floaters in the eyes, seeing flashes of light or other vision changes
Muscle spasms, numbness, or dry mouth and tongue